Biotech | March 10, 2022
Gufic Biosciences collaborates with Selvax for cancer treatment
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
It is also setting up laboratories in West Bengal, Assam, Bihar, Jharkhand and Orissa to comprehensively cater to the East India region
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
Subscribe To Our Newsletter & Stay Updated
